

eISSN: 2581-9615 CODEN (USA): WJARAI Cross Ref DOI: 10.30574/wjarr Journal homepage: https://wjarr.com/

WJARR	HISSN 2561-8615 CODEN (UBA): HUMAN			
	WJARR			
v A	forld Journal of			
Resea	arch and			
	Reviews			
	World Journal Series INDIA			
Check for undates				

# Ayurvedic management of *Tamakshwasa* with special reference to *Bronchial Asthma:* A case study

Sachinkumar Sahebrao Patil\*, Vijayalaxmi Sujay Patil and Arjun Annasaheb Sable

Department of Kayachikitsa, M.A.M.'s Sumatibhai Shah Ayurved Mahavidyalaya, Malwadi, Hadapsar, Pune – 411028, Maharashtra State, India.

World Journal of Advanced Research and Reviews, 2022, 14(02), 333–338

Publication history: Received on 02 April 2022; revised on 10 May 2022; accepted on 12 May 2022

Article DOI: https://doi.org/10.30574/wjarr.2022.14.2.0408

# Abstract

**Introduction:** According to *Ayurveda, Shwasa Vyadhi* is group of symptoms like *Sakashta Shwasa* (breathlessness), *Atiswedapravartana* (excessive sweating), *Hrutpeeda* (mild chest pain). *Tamakshwasa* can be correlated with Bronchial Asthma due to its signs and symptoms.

**Objectives:** To study the effect of *Bibhitaki, Shunthi, Pippali, Shwaskuthar Rasa* with *Madhu* for *Lehana* in *Vegavastha* and *Avegavastha* of *Shwasa Vyadhi.* 

**Material and Methods:** A 55 yrs/Male patient who was a K/C/O Bronchial Asthma since 4 years came to OPD with the above mentioned symptoms. He was admitted in ward for 4 days. He was treated with *Bibhitaki (1gm), Shunthi* (500mg), *Pippali* (500mg), *Shwaskuthar Rasa* (125mg) Lehana during hospital stay as well as on OPD basis over the period of 15 days as an adjuvant treatment. During treatment at outpatient department, periodic follow ups were taken for assessment. Concomitant treatment included.

Since 3 years patient was taking treatment for Bronchial Asthma. Addition of *Bibhitaki (1gm), Shunthi (500mg), Pippali (500mg), and Shwaskuthar Rasa (125mg) Lehana* showed promising

Results as it acts on *PranavahaSrotas*. It helped to reduce the symptoms of *Shwasa Vyadhi* like breathlessness, excessive sweating, and mild chest pain.

**Observations:** There was significant reduction in symptoms such as *SakashtaShwasa* (breathlessness), *Atiswedapravartana* (excessive sweating), *Hrutpeeda* (mild chest pain). Clinically, there was significant reduction in wheezing also. Visual Analogue Scale (VAS scale) was applied for evaluation of all above symptoms. It was observed that Visual Analogue Scale (VAS scale) score also improved after the treatment.

**Conclusion:** Bibhitaki (1 gm), Shunthi (500 mg), Pippali (500 mg), Shwaskuthar Rasa (125 mg) are effective in Vegavastha and Avegavastha of Shwas Vyadhi as an adjuvant treatment along with concomitant medications.

Keywords: Bibhitaki; Shunthi; Pippali; Shwaskuthar Rasa; Bronchial Asthma; Tamakshwasa

\*Corresponding author: Sachinkumar Sahebrao Patil

Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

Department of Kayachikitsa , M.A.M.'s Sumatibhai Shah Ayurved Mahavidyala, Malwadi, Hadapasar, Pune, Maharashtra, India - 411028.

# 1. Introduction

Acharya Charak has classified Shwas Vyadhi in five different types <sup>[1]</sup>. Pranavaha Srotas Dushti is one of the major factors for Shwas Vyadhi<sup>[2]</sup>. Vata Prakopa and Mithyavihara are the factors responsible for Pranavaha Srotas Dushti. Acute onset of Breathlessness, Sweating, difficulty in breathing increased Respiratory Rate are the most prominent symptoms<sup>[3]</sup> of Shwasa Vyadhi observed in Vegawastha<sup>[4]</sup>. Mild chest pain, cough with expectoration, dyspnoea on exertion<sup>[5]</sup> are the symptoms of Shwasa Vyadhi in Avegvastha. All the above mentioned symptoms of Shwasa Vyadhi are due to Pranavaha Srotas Dushti, Stiffness and inflammation of Pranavaha Srotas.

Sthanashrita Kaphadosha leads to these symptoms. Shwaskuthar Rasa is effective drug in Shwasa Vyadhi because of its Ushna Veerya and Sukshma Guna which acts on Pranavaha Srotas. Madhu as Anupana plays key role in action of Shwaskuthar Rasa. This case of ShwasVyadhi Vegavastha and Avegavastha was managed with Shwaskuthar Rasa as an adjuvant to concomitant medications.

# 2. Case Report

Patient name A.B.C. 55 years/male

С/о-

- Breathlessness
- Excessive sweating
- Cough with expectoration
- Mild chest pain all symptoms are seen since 1-2days.

## Asthavidha Pariksha

- Nadi- 112/min.
- Mala-Samakya
- Mootra- Samakya
- Jivha- Nirama
- Shabd-Ksheen
- Sparsha-anushna
- Druk-prakrut
- Akruti-madhyam

Systemic eamxination

RS - Bilateral wheezing, AEBE

CVS-S1S2 Tachy

CNS- Conscious, oriented

P/A- Soft.

R.R.-42/min

SPO2-91% in room air

K/c/o – Bronchial Asthma since 3 years.

On regular treatment

- Nebulisation with Duolin at home SOS
- Tablet Deriphylline 150mg 1BD
- Management

*Bibhitaki* (1gm), *Shunthi* (500mg), *Pippali* (500mg), *Shwaskuthar Rasa is given 1 Gunja* (125 mg) in 3 divided doses with *Madhu as Anupana* for 15 Days.

During IPD stay patient was treated with

- Injection Augmentin 1.2 gm IV TDS x 4 days
- Syrup Ascoril 2 tsf TDS x 4 days
- Duolin nebulisation 6 hourly and Budecort nebulisation 8 hourly x 4 days

On discharge

He was shifted on Foracort (200) Rota caps 2 puffs BID and *Bibhitaki* (1gm), *Shunthi* (500mg) *Pippali* (500mg), *Shwaskuthar Rasa* (125mg) with *Madhu* for *lehana* for 15 days.

**Table 1** Assessment of the patient before treatment, mid treatment and after treatment. (By VAS SCALE) Mild (1-3),Moderate (4-6), Severe (6-9)

SYMPTOMS	Before Treatmentday0 Day 8		AfterTreatmentday15	
Sakashthashwas	9	6	3	
Swedapravrutti	7	3	3	
Hrutpeeda	7	5	3	
Sakaphakasa	8	8	7	
Wheezing	9 7		3	
RR	42/min.	28/min.	18/min.	
SPO2	88@RA(roomair)	92@RA(roomair)	94@RA(roomair)	

# 3. Discussion



Figure 1 Samprapti of Shwasa Vyadhi



## Probable mode of action of Shwaskuthar Rasa [8]Lehana in Shwasa Vyadhi

#### Figure 2 Mode of action of Shwaskuthar Rasa

Table 2	Drug	content and	mode o	faction
I abic 2	Diug	content and	mout o	1 action

Drug Name	Bibhitaki	Pippali	Shunthi
Latin Name	TerminaliaBelerica(Roxb.)	PipperLongum (Linn.)	Zinger Officinale (Roxb)
Family	Combretecae	Piperaceae	Zingiberaceae
Upayuktanga	Phala(Fruits)	Phala (Fruits)	Mula(Roots)
Rasa	Kashaya	Katu	Katu
Vipak	Madhur	Katu	Katu
Veerya	Ushna	Ushna	Ushna
Guna	Laghu,Teekshna, KaphaPittanashak	Laghu, Rukshna, Teekshna, Vata and Kaphanashak	Laghu, Ruksha, Tikshna.
Uses	Anti-inflammatory	Expectorant and it purifies all Dhatus, it strenghthens the lungs.	Anti-inflammatory

# 4. Mode of Action

- Due to microcellular penetration of *Paradha* (Mercury) and kinetic effect of *Paradha* the Drug can reach microcellular structure and can open the channels thus reducing blockage and inflammation.<sup>[9]</sup> Drug will reach *Sukshmasrotas* due to its *Yogavahi Guna* (kinetic energy) also the channel get open due to its *Kashya-Tikta Rasa* and *Ushnaveerya*.
- *Gandhak* is anti-inflammatory and antihistaminic in nature. It will cause reduction in secretion of IgE which is responsible for immune responses thus by reducing IgE it will help for normal passage of air.<sup>[10]</sup>
- *Paradha* (Mercury) having higher molecular weight but due to its micro cellular penetration it can penetrate up to microcells and hence will produce the effect.<sup>[11]</sup>
- Antimicrobial activity of Mansheela <sup>[12]</sup>250 mg/ml concentration of Mansheela bhasma showed 100% inhibition result on Streptococcus pneumonia and Staphylococcus aureus but 75% on Klebsiella pneumonia and 50% on Pseudomonas aeruginosa. In 200 mg/ml conc. of Mansheela Bhasma showed 75% inhibition result on Streptococcus pneumonia, 50% on Staphylococcus aureus, and 250% on Klebsiella pneumonia but no any antimicrobial effect seen on Pseudomonas aeruginosa. So Mansheela Bhasma has antibacterial property on

Gram +ve> Gram –ve. In 150mg/ml concentration of *Hartala Bhasma* no any antimicrobial effect was seen on Gram +ve and Gram –ve bacteria.

• *Mansheela* is anti-inflammatory thus reducing inflammation in airways. *Ushna Veerya* and it acts on *Pranavaha Strotasa*. It also acts *on Kapha Dosha* by *Kaphavilayana* action. It will also open the channels to create good air entry.

The promising results in signs and symptoms are observed. Here the medication was administered in acute exacerbation stage. Its administration in *Avegavastha* (non exacerbation stage) on regular basis may play a key role in reducing the frequency of acute exacerbation attacks, requirement of hospitalization. It may also produce betterment in pulmonary functions by maintaining optimum oxygen saturation for longer duration, keep the patient in mobile, self-dependent stage and thereby improve quality of life of patient.

## 5. Conclusion

*Bibhitaki* (1gm), *Pippali* (500mg), *Shunthi* (500mg), *Shwaskuthar Rasa* (125mg) is effective in *Vegavastha* and *Avegavastha* of *Shwasa Vyadhi* in three divided doses as an adjuvant. It has beneficial effect in reducing symptoms like *Sakashthashwasa, Swedpravrutti*, and *Hrutpeeda, SakaphaKasa*, reducing signs like increase in Respiratory Rate and wheezing also.

#### Further scope

These findings were noted in a single case. But to prove its efficacy further studies can be carried out on large sample size, for longer duration in *Vegavastha* as well as *Avegavastha* of *Shwasa Vyadhi*.

## **Compliance with ethical standards**

#### Acknowledgments

We express our gratitude to the Department of Kayachikitsa and Hospital Authority for giving us this opportunity to study this particular case: Ayurvedic management of *Tamakshwasa* with special reference to *Bronchial Asthma:* A case study.Special thanks to Secretary of Maharashtra Arogya Mandal's Secretary, Hon'ble Mr. Anil Gujar, Hon'ble Principal Dr. Nilesh Phule and Faculty members for co-operating, also thanks to the teachers Dr. Ritesh Damle, Dr. Kiran Ubhe, for guiding throughout to provide better management of the patient. Many thanks to my colleagues, as we got to learn many new things while studying the case and our knowledge regarding the subject has been increased.

#### Disclosure of conflict of interest

The authors declare that there was no conflict of interest regarding the publication of manuscript.

#### Statement of informed consent

Informed consent was obtained from the individual participant included in the study.

#### References

- [1] Harishchandra Singh Kushavaha, Charak Samhita Chikitsasthan, Varanasi: Chaukhambha Orientalia : 2014; 17/18; Page No 533.
- [2] Vd. Sidhinandan Mishra, Hindi Vyakhyakar- Vd. Harishchandra Singh Kushavaha, Charak Samhita Chikitsasthan , Varanasi: Chaukhambha Orientalia, 2014; 17/17; Page No 533.
- [3] Edited by Fauci, Kasper, Longo, Jameson, Loscalzo, HARRISON'S Principles of Internal Medicine, 19th Edition.
  (2): 1669-1676.
- [4] Vd. Sidhinandan Mishra, Hindi Vyakhyakar- Vd. Harishchandra Singh Kushavaha Charak Samhita Chikitsasthan, Varanasi: Chaukhambha Orientalia, 2014; 17/61; Page No 534.
- [5] Edited by Nicki R. Colledge, Brian R. Walker, Stuart H. Ralston, Davidson's Principles & Practice of Medicine. 22ndEdition. Publication Churchill Livingstone Elsevier ,Page No 668.

- [6] Kaviraj, Dr. Ambika Datta Shastri Sushrut Samhita Uttarasthan, Edition: Reprint. Varanasi: Chaukhambha Sanskrit Sansthan, 2009; 51/6; Page No 476.
- [7] Vd. Sidhinandan Mishra, Hindi Vyakhyakar- Vd. Harishchandra Singh Kushavaha Charak Samhita Chikitsasthan, Varanasi: ChaukhambhaOrientalia, 2014; 17/19-21; Page No 533.
- [8] Acharya Gangadharshastri Gune Ayurvediya Aushadhigundharmshastra. Delhi: Chaukhambha Sanskrit Prakashan; 2014; Page No 59.
- [9] Mythili krishna S, Richard Gaude, Arun B. Joshi, Songnificance of parad in Rasashatra A review, J Ayu HerbMed September 2017 Vol 3 Issue 3 Page No 169-174.
- [10] C.Y. Jagtap quality control parameters for Tamra Bhasma, Paradha, Swarna, Gandhaka, 2012; 173-83. Available from www. ncbi.nlm.nih.gov
- [11] C.Y. Jagtap quality control parameters for Tamra Bhasma, Paradha, Swarna, Gandhaka, 2012; 173-89. Available from www.ncbi.nlm.nih.gov
- [12] Garg Lokesh Kumar, et.al. Pharmaceutico analytical study and comparative antimicrobial effect of Hartala Bhasma and Hartalagodanti Bhasma. Int. J. Ayur. Pharma Research. 2013; Page No 36-46.

## Author's short Biography

